2,429 results match your criteria Autoimmunity reviews[Journal]


Immune checkpoint inhibitors-induced autoimmunity: The impact of gender.

Autoimmun Rev 2020 Jun 17:102590. Epub 2020 Jun 17.

Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy.

Objective: To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune checkpoint inhibitors (ICIs) in accordance with the gender of treated cancer patients.

Methods: A systematic review of the medical literature was conducted by searching all available clinical data up to December 2019 in several databases using a combination of MESH terms related to immune checkpoint inhibitors, autoimmunity, and gender. Analyzed data were related to all FDA approved ICIs and respective indications in cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102590DOI Listing

The immunologic etiology of psychiatric manifestations in systemic lupus erythematosus: A narrative review on the role of the blood brain barrier, antibodies, cytokines and chemokines.

Autoimmun Rev 2020 Jun 17:102592. Epub 2020 Jun 17.

Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht 3584 CX, the Netherlands. Electronic address:

Introduction: The aim of this narrative review is to provide an overview of the literature on the possible immunologic pathophysiology of psychiatric manifestations of neuropsychiatric systemic lupus erythematosus (NPSLE).

Methods: A systematic search on PubMed was conducted. English studies with full text availability that investigated the correlation between blood-brain barrier (BBB) dysfunction, intrathecal synthesis of antibodies, antibodies, cytokines, chemokines, metalloproteinases, complement and psychiatric NPSLE manifestations in adults were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102592DOI Listing

Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma.

Autoimmun Rev 2020 Jun 14:102587. Epub 2020 Jun 14.

Department of Dermatology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, Barcelona, Spain.

Therapy for advanced melanoma has deeply changed in the last decade with the introduction of checkpoint and BRAF/MEK inhibitors. Granulomatous reactions have been reported related to these drugs. We performed a systematic review of all the cases described in the medical literature by the search (("Melanoma"[Mesh]) AND ("Sarcoidosis"[Mesh] OR "Granuloma"[Mesh])). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102587DOI Listing

Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets.

Autoimmun Rev 2020 Jun 14:102583. Epub 2020 Jun 14.

Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Systemic sclerosis (SSc) is a rare chronic disease of unknown etiology characterized by vascular abnormalities and fibrosis involving the skin and internal organs, especially the gastrointestinal tract, lung, heart and kidneys. Although the disease was historically stratified according to the extent of skin involvement, more recent approaches place more emphasis on patterns and extent of internal organ involvement. Despite numerous clinical trials in SSc, disease-modifying treatment options are still limited resulting in persistent poor quality of life and high mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102583DOI Listing

Risk of scleroderma according to the type of immune checkpoint inhibitors.

Autoimmun Rev 2020 Jun 12:102596. Epub 2020 Jun 12.

Regional Center of Pharmacovigilance, Department of Pharmacology, Cochin Hospital, Paris, France.

Introduction: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Among them, ICIs-induced systemic sclerosis (SSc) is poorly known.

Methods: To better characterize this irAE, our comprehensive approach combined the description of ICIs-induced scleroderma cases, the systematic review of the literature and the analysis of VigiBase, the WHO pharmacovigilance database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102596DOI Listing

Immunomodulatory therapeutic effects of curcumin in rheumatoid arthritis.

Autoimmun Rev 2020 Jun 12:102593. Epub 2020 Jun 12.

Halal Research center of IRI, FDA, Tehran, Iran; Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102593DOI Listing
June 2020
7.933 Impact Factor

Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy.

Autoimmun Rev 2020 Jun 12:102589. Epub 2020 Jun 12.

Clinical and Surgical Sciences, University of Trieste, Trieste, Italy.

Hepatitis C virus (HCV) infection affects about 70 million people worldwide. HCV is responsible for both hepatitis and extra-hepatic manifestations. Chronic infection has been shown to develop in about 70% of cases and can progress to cirrhosis or hepatocellular carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102589DOI Listing

A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: A pilot study.

Autoimmun Rev 2020 Jun 12:102588. Epub 2020 Jun 12.

Laboratorio di Patologia Clinica, Ospedale San Antonio, Tolmezzo, Italy.

The commercial tests currently available as second-level tests to detect ANA sub-specificities are generally used independently from the ANA immunofluorescence (IIF) pattern. The aim of this study was to evaluate the efficacy of the use of a customizable pattern-oriented antigenic panel by immunoblot (IB) using the International Consensus on ANA Patterns (ICAP) classification scheme, in order to introduce a novel and updated autoimmune diagnostic flowchart. 710 sera referred for routine ANA testing were selected on the basis of the ANA pattern according to the ICAP nomenclature (nuclear speckled AC-2,4,5; nucleolar AC-8,9,10,29; cytoplasmic speckled AC 18,19,20) and on an IIF titer ≥1:320. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102588DOI Listing

Molecular mimicry may explain multi-organ damage in COVID-19.

Autoimmun Rev 2020 Jun 11:102591. Epub 2020 Jun 11.

University of Palermo, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Palermo, Italy; Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289093PMC

Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.

Autoimmun Rev 2020 Jun 11:102586. Epub 2020 Jun 11.

Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Regional Pharmacovigilance Centre, Department of Pharmacology, Sorbonne Université, INSERM CIC Paris-Est, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France. Electronic address:

Background: In addition to restoring anti-tumor immune responses, immune checkpoint inhibitors (ICI) may also induce immune-related adverse events (irAE) that can affect any organ. We aim to determine the spectrum, timing, clinical features, and fatalities of rheumatic and musculoskeletal Immune-related adverse events (RMS-irAE) associated with ICI.

Patients Methods: We performed an observational, retrospective, pharmacovigilance study using the World Health Organization international pharmacovigilance database, VigiBase, from inception to January 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102586DOI Listing

Covid-19 and autoimmunity.

Autoimmun Rev 2020 Jun 11:102597. Epub 2020 Jun 11.

The Zabludowicz Center for autoimmune diseases, Sheba Medical Center, Israel; The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Sechenov University, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289100PMC

Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.

Autoimmun Rev 2020 Jun 11:102595. Epub 2020 Jun 11.

Division of Rheumatology, University of British Columbia, Vancouver, British Columbia, Canada.

Objective: Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related adverse events (irAE). Here we describe the clinical presentation and management of rheumatic immune-related adverse events (Rh-irAE) in a national multi-center cohort.

Methods: All patients presenting with Rh-irAE at 9 academic sites across Canada between January 2013 and January 2019 were identified and included in this retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102595DOI Listing

Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome.

Autoimmun Rev 2020 Jun 12:102594. Epub 2020 Jun 12.

Campus Kerckhoff of Justus Liebig University Giessen, Dept. of Rheumatology, Immunology, Osteology and Physical Medicine, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102594DOI Listing

Pentraxin 3: A promising therapeutic target for autoimmune diseases.

Autoimmun Rev 2020 Jun 10:102584. Epub 2020 Jun 10.

Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China; Anhui Province Key Laboratory of Major Autoimmune Diseases, 81 Meishan Road, Hefei, Anhui, China. Electronic address:

Pentraxin 3 (PTX3) is a prototypic humoral soluble pattern recognition molecule that exerts a pivotal role in innate immune response and inflammation, as well as in tissue damage and remodeling. Recently, emerging evidence has revealed that PTX3 is involved in the occurrence and development of various autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), systemic sclerosis (SSc), inflammatory bowel disease (IBD), multiple sclerosis (MS) and psoriasis, etc. In this review, we have succinctly summarized the complex immunological functions of PTX3 and mostly focused on recent findings of the pleiotropic activities played by PTX3 in the pathogenesis of autoimmune diseases, aiming at hopefully offering possible future therapeutic alternatives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102584DOI Listing
June 2020
7.933 Impact Factor

Hydroxychloroquine reduces IL-6 and pro-thrombotic status.

Autoimmun Rev 2020 07 12;19(7):102555. Epub 2020 May 12.

Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102555DOI Listing

COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?

Autoimmun Rev 2020 Jul 5;19(7):102573. Epub 2020 May 5.

Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Rheumatology Unit, Sapienza University of Rome, Rome, Italy.

The severe form of COVID-19 share several clinical and laboratory features with four entities gathered under the term "hyperferritinemic syndromes" and including macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD), catastrophic anti-phospholipid syndrome (CAPS) and septic shock. COVID-19 systemic inflammatory reaction and "hyperferritinemic syndromes" are all characterized by high serum ferritin and a life-threatening hyper-inflammation sustained by a cytokines storm which eventually leads to multi-organ failure. In this review, we analyze the possible epidemiological and molecular mechanisms responsible for hyper-inflammation in patients with severe COVID-19 and we underline the similarities between this condition and "hyperferritinemic syndromes" which would allow considering severe COVID-19 as a fifth member of this spectrum of inflammatory conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102573DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199723PMC

Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.

Autoimmun Rev 2020 07 5;19(7):102563. Epub 2020 May 5.

St. John's Institute of Dermatology, Guy's and St Thomas' Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198409PMC

Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients?

Autoimmun Rev 2020 07 5;19(7):102558. Epub 2020 May 5.

Department of Rheumatology, Gaetano Pini Hospital, Milan, Italy; University of Milan, Dept. of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198424PMC

Convalescent plasma in Covid-19: Possible mechanisms of action.

Autoimmun Rev 2020 Jul 5;19(7):102554. Epub 2020 May 5.

Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia. Electronic address:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102554DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198427PMC
July 2020
7.933 Impact Factor

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.

Autoimmun Rev 2020 Jul 5;19(7):102566. Epub 2020 May 5.

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Maccabitech, Maccabi Healthcare Services, Tel Aviv, Israel.

Background: Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear.

Methods: This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102566DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198406PMC

Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies.

Autoimmun Rev 2020 Jul 3;19(7):102571. Epub 2020 May 3.

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy. Electronic address:

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics are yet available to control disease evolution, more in-depth understanding of the pathogenic mechanisms induced by SARS-CoV-2 will help to characterize new targets for the management of COVID-19. The present study identified a specific set of biological pathways altered in primary human lung epithelium upon SARS-CoV-2 infection, and a comparison with SARS-CoV from the 2003 pandemic was studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252184PMC

Fatal COVID-19 infections: Is NK cell dysfunction a link with autoimmune HLH?

Autoimmun Rev 2020 07 3;19(7):102561. Epub 2020 May 3.

Department of Medicine, University of Alberta, Edmonton, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102561DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252043PMC

Cytokine storm syndrome in severe COVID-19.

Autoimmun Rev 2020 07 3;19(7):102562. Epub 2020 May 3.

Division of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102562DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252135PMC

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.

Autoimmun Rev 2020 Jul 3;19(7):102568. Epub 2020 May 3.

University Division of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, Brescia, Italy; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. Electronic address:

A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 (IL-6) receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8 mg/kg by two consecutive intravenous infusions 12 h apart. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102568DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252115PMC

Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view.

Autoimmun Rev 2020 Jul 3;19(7):102570. Epub 2020 May 3.

Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

Now COVID-19 is causing a severe public health emergency and the mortality is rapidly increasing all over the world. In the current pandemic era, although there have been many efforts to diagnose a number of patients with symptoms or close contacts, there is no definite guideline for the initial therapeutic approach for them and therefore, many patients have been dying due to a hyperinflammatory immunological reaction labeled as "cytokine storm". Severe patients are hospitalized and the treatment is done, though they have not been established yet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102570DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252097PMC

SARS-CoV-2 infection among patients with systemic autoimmune diseases.

Autoimmun Rev 2020 Jul 5;19(7):102575. Epub 2020 May 5.

Department of Experimental and Clinical Medicine, University of Firenze, Italy.

Objectives: This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population.

Methods: In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection.

Results: 458 patients were interviewed [74% female, median age 56 years (IQR 43-68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200134PMC

Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.

Autoimmun Rev 2020 Jul 3;19(7):102569. Epub 2020 May 3.

Systemic Autoimmune Research Unit, Vall d'Hebron Research Institute, Barcelona, Spain.

Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called "cytokine storm". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102569DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252146PMC

Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms.

Autoimmun Rev 2020 07 3;19(7):102572. Epub 2020 May 3.

ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252120PMC

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.

Autoimmun Rev 2020 Jul 4;19(7):102567. Epub 2020 May 4.

Department of Internal Medicine, Lyon University Hospital, Lyon, France.

The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December 2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up extraordinary challenges. This unprecedented situation led to the inception of numerous fundamental research protocols and many clinical trials. It quickly became apparent that although COVID-19, in the vast majority of cases, was a benign disease, it could also develop a severe form with sometimes fatal outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196557PMC

The correlation between SARS-CoV-2 infection and rheumatic disease.

Autoimmun Rev 2020 07 1;19(7):102557. Epub 2020 May 1.

Department of Clinical Diagnosis, Tangdu Hospital, Air Force Medical University, Xinsi Road, Xi'an, Shanxi 710038, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194066PMC
July 2020
7.933 Impact Factor

SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?

Autoimmun Rev 2020 07 1;19(7):102559. Epub 2020 May 1.

Department of Biomedical Science and Human Oncology (DIMO), Systemic Rheumatic and Autoimmune Diseases Unit, University of Bari Medical School, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102559DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252087PMC

Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons.

Autoimmun Rev 2020 07 1;19(7):102556. Epub 2020 May 1.

Universitätsmedizin Greifswald, Department of Neurology, Greifswald, Germany; German Center for Neurodegenerative Diseases, Rostock/Greifswald, Greifswald, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102556DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252083PMC

Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection.

Autoimmun Rev 2020 07 1;19(7):102560. Epub 2020 May 1.

Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252008PMC

Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.

Authors:
Yehuda Shoenfeld

Autoimmun Rev 2020 Jun 5;19(6):102538. Epub 2020 Apr 5.

Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Tel-Aviv University, Israel; Laboratory of the Mosaics of Autoimmunity, Saint Petersburg State University, Saint-Petersburg, Russian Federation. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131471PMC

ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia.

Autoimmun Rev 2020 Jun 3;19(6):102536. Epub 2020 Apr 3.

Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195011PMC

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.

Autoimmun Rev 2020 Jun 3;19(6):102537. Epub 2020 Apr 3.

Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK.

Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency states termed primary HLH -with radically different therapy strategies in both situations. COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195002PMC

What is the role of rheumatologists in the era of COVID-19?

Autoimmun Rev 2020 Jun 3;19(6):102539. Epub 2020 Apr 3.

Rheumatology Unit, ASST-Fatebenefratelli L, Sacco University Hospital, University of Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129715PMC

A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors.

Autoimmun Rev 2020 Jun 1;19(6):102527. Epub 2020 Apr 1.

Institute for Medical Immunology, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany. Electronic address:

Myalgic Encephalomyelitis or Chronic Fatigue Syndrome (CFS/ME) is a complex and severely disabling disease with a prevalence of 0.3% and no approved treatment and therefore a very high medical need. Following an infectious onset patients suffer from severe central and muscle fatigue, chronic pain, cognitive impairment, and immune and autonomic dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102527DOI Listing

In utero exposure to Azathioprine in autoimmune disease. Where do we stand?

Autoimmun Rev 2020 Mar 30:102525. Epub 2020 Mar 30.

Rheumatology and Clinical Immunology Unit, University of Brescia, Brescia, Italy.

Azathioprine (AZA), an oral immunosuppressant, is safe during pregnancy. Some reports suggested different impairments in the offspring of mothers with autoimmune diseases (AI) exposed in utero to AZA. These observations are available from retrospective studies or case reports. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102525DOI Listing
March 2020
7.933 Impact Factor

Microbiota and metabolites in rheumatic diseases.

Autoimmun Rev 2020 Mar 30:102530. Epub 2020 Mar 30.

Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address:

As a gigantic community in the human body, the microbiota exerts pleiotropic roles in human health and disease ranging from digestion and absorption of nutrients from food, defense against infection of pathogens, to regulation of immune system development and immune homeostasis. Recent advances in "omics" studies and bioinformatics analyses have broadened our insights of the microbiota composition of the inner and other surfaces of the body and their interactions with the host. Apart from the direct contact of microbes at the mucosal barrier, metabolites produced or metabolized by the gut microbes can serve as important immune regulators or initiators in a wide variety of diseases, including gastrointestinal diseases, metabolic disorders and systemic rheumatic diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102530DOI Listing

Rheumatoid arthritis in the elderly: Characteristics and treatment considerations.

Autoimmun Rev 2020 Jun 29;19(6):102528. Epub 2020 Mar 29.

Department of Rheumatology and NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

The elderly rheumatoid arthritis (RA) population consists of both elderly-onset RA that manifests after the age of 60 and individuals diagnosed with RA early in life who age naturally to become members of this group. The elderly RA population is expanding due to both increased life expectancy and an increased incidence of elderly onset RA. Elderly onset RA seems to have a characteristic clinical pattern and perhaps biological profile different to that of early onset RA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102528DOI Listing

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review.

Autoimmun Rev 2020 Jun 29;19(6):102526. Epub 2020 Mar 29.

Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

Background: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a monogenic disorder characterized by early onset fatal multi-system autoimmunity due to loss-of-function mutations in the gene encoding the forkhead box P3 (FOXP3) transcription factor which is crucial for the development, maturation, and maintenance of CD4 regulatory T (T-reg) cells. Various autoimmune phenomena such as enteropathy, endocrinopathies, cytopenias, renal disease, and skin manifestations are characteristic findings in patients affected by IPEX syndrome.

Objectives: In this systematic review, we focus on both clinical and demographic characteristics of IPEX patients, highlighting possible genotype-phenotype correlations and address prognostic factors for disease outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102526DOI Listing
June 2020
7.933 Impact Factor

Glaucoma is an autoimmune disease.

Autoimmun Rev 2020 Jun 28;19(6):102535. Epub 2020 Mar 28.

Department of Medicine "T", Souraski Tel Aviv Medical Center, and The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Israel. Electronic address:

Glaucoma is characterized by retinal ganglion cell (RGC) neurodegeneration. Elevated intraocular pressure (IOP) is a major risk factor however, mechanisms independent of IOP play a role in RGC pathology. Both antibodies and CD4 T-cells as well as microbiota take part in the pathogenesis of both glaucoma and rheumatoid arteritis (RA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102535DOI Listing

Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014.

Autoimmun Rev 2020 Jun 29;19(6):102531. Epub 2020 Mar 29.

Centre National de Référence des Maladies Auto-Immunes et Systémiques Rares, Est/Sud-Ouest (RESO), France; Service de rhumatologie, Centre Hospitalier Universitaire de Strasbourg, 1 avenue Molière, 67098 Strasbourg, France; Immuno-rhumatologie moléculaire, INSERM UMR-S 1109, Strasbourg, France. Electronic address:

Aim: To describe changes in the 2001-2014 mortality of 6 autoimmune systemic diseases (AISDs), namely Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathies (IIM), Sjögren's Syndrome (SS), Mixed Connective Tissue Disease (MCTD) and ANCA-associated vasculitis (AAV) at the country-, continent-, and world-levels.

Methods: Mortality data were retrieved from the World Health Organization (WHO) mortality database for each disease, based on ICD-10 codes. We computed age-standardized mortality rate (ASMR) as the estimated number of deaths per million inhabitants and its 95% confidence interval (95%CI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102531DOI Listing

Autoimmune thyroid disorders and rheumatoid arthritis: A bidirectional interplay.

Autoimmun Rev 2020 Jun 29;19(6):102529. Epub 2020 Mar 29.

Rheumatology, Allergy and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.

Rheumatoid arthritis (RA) and autoimmune thyroid disease (AITD) can occur in the same patient in the autoimmune polyglandular syndrome 2. The association of the two conditions has been recognized long-time ago and the prevalence of AITD in patients with RA and vice versa is well assessed. Geographical variation of AITD and related autoantibodies in RA patients is partly due to ethnic and environmental differences of the studied populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102529DOI Listing

Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.

Autoimmun Rev 2020 Jun 28;19(6):102533. Epub 2020 Mar 28.

Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA; VA Palo Alto Health Care System, Palo Alto, CA, USA. Electronic address:

Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy characterized by muscle weakness and cutaneous manifestations in adults and children. Calcinosis, a complication of DM, is the abnormal deposition of insoluble calcium salts in tissues, including skin, subcutaneous tissue, tendons, fascia, and muscle. Calcinosis is more commonly seen in juvenile DM (JDM), but also develops in adult DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225028PMC